학술논문

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial
Document Type
Article
Source
In The Lancet Respiratory Medicine November 2021 9(11):1299-1312
Subject
Primary Research
Articles
Language
ISSN
2213-2600